IXO Private Equity invests 2,7M€ in Cyclopharma

Created in 2000 on the Biopole Clermont-Limagne, Cyclopharma is the French leader specialized in the development and the marketing of solutions of molecular imaging for the management of the patient both in oncology and in neurology.

The capital increase will so allow to finance the research for new molecules biomarkers and the development of its international activity, in particular in the United States and in Europe.
Based on the site of Saint-Beauzire, Cyclopharma realizes more than 20 M€ of turnover and employs 119 collaborators distributed on the seat and 7 production sites, the meshing of the territory of which is adapted to the constraints of this short half-life drugs.

Cyclopharma develops, produces and markets radiotracers who are used to realize positron emission tomography (PET) medical imaging. The use of this radiopharmaceutical medicine coupled with the PET technology meets the healthcare professionals’ and patients’ needs by allowing a diagnosis of the whole body and a coverage more adapted to their pathology.
Since 2013, Cyclopharma is mainly detained by Denos Pharma, who participates in the operation. The capital increase of a total amount of 5,4 M€ is thus signed by iXO Private Equity at the level of 2,7 M€, Denos Pharma at the level of 1,9 M€, Sofimac at the level of 0,6 M€, and other already present shareholders for the balance.

The team organized at that time, taken by the Managing director Bernard Landes, emphasized the Research and development by rationalizing the projects and by increasing significantly the R&D budget. It increased twofold since 2014 and represents from now on more than 10 % of the turnover. Today, these efforts pay off, and two new molecules, used for the diagnosis of the breast and the prostate cancers, have been granted marketing authorization in France and are about to be in phase of commercial launch.

In parallel, Cyclopharma moves forward on development projects which will allow the company to complete its offer (2 molecules at the clinical testing stage) and its geographic coverage, in Europe and in the United States.


Biopôle Clermont-Limagne
Mathilde Bouscaillou
Phone: +33 (0) 473 632 822
Email: mbouscaillou@cyclopharma.fr
Website: www.cyclopharma.fr